title: Individualizing osteoporosis medications.
abstract: Mrs. JD is a 58-year-old postmenopausal woman having symptoms of hot flashes and night sweats. She has a dual-energy x-ray absorptiometry T-score of -2.4 in the femoral neck, consistent with low bone mass or osteopenia. She has a parental history of hip fracture. FRAX shows the 10-year absolute risk of major osteoporotic fracture equal to 18% and the 10-year risk of hip fracture above 3% at 3.2%, which meets the National Osteoporosis Foundation threshold. Mrs. JD is taking calcium 1,200 mg, between supplement and diet, and 1,000 IU vitamin D3 daily. How should she be treated?
authors: From the Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, OMC Clinical Research Center, Los Angeles, California.
authors: Stuart
authors: S
authors: Silverman
mesh_terms: D015502:Absorptiometry, Photon; D000281:Administration, Intranasal; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D015519:Bone Density; D050071:Bone Density Conservation Agents; D002116:Calcitonin / Q000008:administration & dosage / Q000009:adverse effects; D002136:Calcium, Dietary / Q000008:administration & dosage; D000069448:Denosumab; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006620:Hip Fractures / Q000517:prevention & control; D019584:Hot Flashes; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000000981:diagnostic imaging / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000517:prevention & control; D057285:Precision Medicine; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors; D014807:Vitamin D / Q000008:administration & dosage
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D002136:Calcium, Dietary; D004164:Diphosphonates; D014807:Vitamin D; D000069448:Denosumab; D020849:Raloxifene Hydrochloride; D002116:Calcitonin